Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
InnoCare launched book building to raise up to USD 288 million to list in Hong Kong. In our previous notes, we have covered the company’s key pipeline products, orelabrutinib (ICP-022, BTK), ICP-192 (pan-FGFR), and ICP-105 (FGFR4). We think orelabrutinib is promising in terms of both efficacy and safety profile, compared to its reference drug ibrutinib, but competition will be intense for the indication. In addition, BTK inhibitors haven’t achieved success outside lymphoma indications and ...
InnoCare Pharma Limited is a clinical-stage biopharmaceutical company with a focus on small molecule inhibitors for BTK, and FGFRs. The company will start pre-marketing for a USD 200 million IPO for its Hong Kong listing soon. In our previous note, we discussed the background of its key drug candidates under clinical trials, including orelabrutinib (ICP-022, BTK), ICP-192 (pan-FGFR), and ICP-105 (FGFR4). We think orelabrutinib is promising in terms of both efficacy and safety profile, compared...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.